Filtered By:
Vaccination: Influenza Vaccine

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 6499 results found since Jan 2013.

He battled AIDS, COVID-19, and Trump. Now, Anthony Fauci is stepping down
Anthony Fauci, the renowned physician-scientist who has led the $6.3 billion National Institute of Allergy and Infectious Diseases (NIAID) for nearly 4 decades and since early 2020 has been the U.S. government’s voice of scientific reason during the COVID-19 pandemic, will step down from government service in December. Fauci, 81, had said in recent interviews that he planned to retire from the government by the end of President Joe Biden’s administration, but did not give a date until today. He said in a statement that although leading NIAID “has been the honor of a lifetime,” he plans to “pursue...
Source: Science of Aging Knowledge Environment - August 22, 2022 Category: Geriatrics Source Type: research

High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review
ConclusionsInfluenza exerts a considerable burden on adults aged ≥ 65 years and healthcare systems, with high incidence of hospitalization and mortality. Substantial influenza-associated clinical burden persists despite increasing vaccination coverage among adults aged ≥ 65 years across regions included in this review, which suggests limited effectivene ss of currently available seasonal influenza vaccines. To reduce influenza-associated clinical burden, influenza vaccine effectiveness must be improved. Next generation vaccine production using mRNA technology has demonstrated high effectiveness against another re...
Source: Advances in Therapy - February 15, 2023 Category: Drugs & Pharmacology Source Type: research

Dispute simmers over who first shared SARS-CoV-2 ’s genome
When GISAID, the widely used database for influenza and SARS-CoV-2 genomes, issued a statement last week about a set of controversial sequences from the Huanan Seafood Wholesale Market in Wuhan, China, the release explained by way of background that the repository was “an essential contributor to global health” trusted by thousands of data contributors from 215 nations and territories. But GISAID also included a claim that has been puzzling and infuriating some virologists for 3 years: It was the place where the first SARS-CoV-2 genomes were publicly shared, on 10 January 2020. That claim challenges contempo...
Source: Science of Aging Knowledge Environment - March 29, 2023 Category: Geriatrics Source Type: research

A chimeric HLA-A2: β2M:Ig fusion protein for the study of virus-specific CD8 < sup > + < /sup > T-cells
CONCLUSION: The chimeric HLA-A2:β2M:Ig fusion protein-based assays provided a sensitive tool that may be paramount to measure virus-specific CD8+ T-cell response in a range of viral infections of clinical relevance.PMID:33600818 | DOI:10.1016/j.jim.2021.112997
Source: Journal of Immunological Methods - February 18, 2021 Category: Allergy & Immunology Authors: Ágata Lopes Ribeiro Franklin Pereira Ara újo Julia Pereira Martins Alice Aparecida Louren ço Jing Huang Felipe Valen ça Pereira Luis Adan Flores Andrade Adriana Alves Oliveira Paim Fl ávio Guimarães da Fonseca Edel Figueiredo Barbosa Stancioli Olind Source Type: research

Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race
CONCLUSION: Each of the four sociodemographic predictors - age, sex, race, and gender - were found to significantly influence vaccine acceptance, receipt and outcomes in this review.PMID:33933316 | DOI:10.1016/j.vaccine.2021.04.013
Source: Vaccine - May 2, 2021 Category: Allergy & Immunology Authors: Aniket Kini Rosemary Morgan Helen Kuo Patrick Shea Janna Shapiro Sean X Leng Andrew Pekosz Sabra L Klein Source Type: research

Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review
CONCLUSIONS: A body of literature is available from which to plan and design future studies of vaccination in pregnant women using RWD. This is of intense importance as new vaccines, such as those for COVID-19, become available to the general population via approval or authorization without inclusion of pregnant women in the clinical trials.PMID:34090699 | DOI:10.1016/j.vaccine.2021.05.071
Source: Vaccine - June 6, 2021 Category: Allergy & Immunology Authors: Tamar Lasky Ann W McMahon Wei Hua Richard Forshee Source Type: research

Healthcare workers' perceptions and experiences of communicating with people over 50 years of age about vaccination: a qualitative evidence synthesis
CONCLUSIONS: There is little research focusing specifically on healthcare workers' perceptions and experiences of communication with older adults about vaccination. The studies we identified suggest that healthcare workers differed among themselves in their perceptions about the aim of this communication and about the role of older adults in vaccine decisions. Based on these findings and the other findings in our review, we have developed a set of questions or prompts that may help health system planners or programme managers when planning or implementing strategies for vaccination communication between healthcare workers ...
Source: Cochrane Database of Systematic Reviews - July 20, 2021 Category: General Medicine Authors: Claire Glenton Benedicte Carlsen Simon Lewin Manuela Dominique Wennekes Brita Askeland Winje Renske Eilers VITAL consortium Source Type: research

Hexavalent vaccines: What can we learn from head-to-head studies?
CONCLUSION: Although the licensed hexavalent vaccines are generally considered similar, analyses of immunogenicity data from head-to-head trials highlighted differences that could be related to differences in composition and formulation. In addition, the demonstrated non-inferiority of the immunogenicity of the more recent vaccines versus DT3aP-HBV-IPV/Hib does not allow a full bridging to similar efficacy, effectiveness and safety. The availability of DT3aP-HBV-IPV/Hib over > 20 years allowed to collect a wealth of data on its long-term immunogenicity, safety and effectiveness in clinical and post-marketing studies, an...
Source: Vaccine - September 17, 2021 Category: Allergy & Immunology Authors: Markus Knuf Herv é Haas Pilar Garcia-Corbeira Elisa Turriani Piyali Mukherjee Winnie Janssens Val érie Berlaimont Source Type: research

Immunosuppression and immunization: Vaccination in pediatric patients with neuromuscular diseases treated with steroids or immune-modulating drugs
CONCLUSION: With just a few exceptions, vaccines are safe in this group of patients and they should receive the same immunizations and according to the same schedule, as all children. Live vaccines should not be administered in patients receiving high dose steroid or immune-modulating drugs such as anti-B cell treatments (rituximab), high dose methotrexate, azathioprine or 6-mercaptopurine. Whenever possible, all live vaccines should be administered prior to long term immune-suppressant treatments. Additional vaccines are recommended in this risk population of children (influenza, pneumococcal, varicella).PMID:34752936 | D...
Source: European Journal of Paediatric Neurology - November 9, 2021 Category: Neurology Authors: Tanja Golli Andrej Kastrin Marko Pokorn Zvonka Rener-Primec Source Type: research

Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders
CONCLUSION: s: There are no strong evidence supporting relationship between vaccination with different pediatric vaccines and development of first episodes or reccurrences of GBS, Bell's palsy, optic neuritis (ON), juvenile MG, CIDP, and IM. The vaccination and revaccination with inactivated vaccines is considered safe in children with medical history of GBS, Bell's palsy, ON, MG and IM. Caution when immunization against influenza, quadrivalent conjugated meningococcal vaccine (MCV4) and pneumococcal disease and avoiding tetanus toxoid immunization in CIDP patients is suggested. Patients with immune mediated acquired NMD s...
Source: European Journal of Paediatric Neurology - January 8, 2022 Category: Neurology Authors: Nina Bari i? Daniel Turudi ? Lorna Stemberger Mari ? Goran Te ovi? Source Type: research

Movement disorders, cerebral palsy and vaccination
Eur J Paediatr Neurol. 2021 Dec 21;36:143-150. doi: 10.1016/j.ejpn.2021.12.006. Online ahead of print.ABSTRACTThis review focused on vaccination in children with movement disorders, including cerebral palsy and the movement disorders triggered by vaccination in children with and without neurological disabilities. The following clinical questions were addressed: 1) Can children with movement disorders be vaccinated? 2) Can vaccination trigger movement disorders in children without neurological disabilities? 3) Can vaccination trigger movement disorders in children with neurological disabilities? and 4) Is there any consensu...
Source: European Journal of Paediatric Neurology - January 3, 2022 Category: Neurology Authors: Zuzana Liba Josef Kraus Tomas Necas Jiri Necas Miloslav Klugar Pavel Krsek Source Type: research

The adverse reactions to vaccines practice parameter 10 years on -what have we learned?
CONCLUSION: The risk of reactions to vaccination should be weighed against the risk of suffering a vaccine-preventable disease if the vaccine is withheld. There is no need to ask about egg allergy prior to the administration of influenza vaccines, including on screening forms. In most cases, an allergy to a vaccine constituent is not a contraindication to the vaccine containing it. Patients who have had possible anaphylactic reactions to vaccines should be evaluated by an allergist rather than simply being labeled allergic, because most can go on to receive subsequent doses. Most immediate reactions to COVID-19 vaccines ar...
Source: Annals of Allergy, Asthma and Immunology - February 1, 2022 Category: Allergy & Immunology Authors: John M Kelso Source Type: research

Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data
CONCLUSIONS: Our study suggests that both adjuvanted and high-dose vaccines are effective alternatives for vaccination programmes in older adults and preferable over conventional standard-dose vaccines.PMID:35459556 | DOI:10.1016/j.vaccine.2022.04.019
Source: Vaccine - April 23, 2022 Category: Allergy & Immunology Authors: B C G ärtner T Weinke K Wahle A Kwetkat D Beier K J Schmidt T F Schwarz Source Type: research